FDA Approves Expansion Of The Medicines Company’s Angiomax(R) Label To Include Patients With Or At Risk Of HIT/HITTS Undergoing PCI; HIT/HITTS Places Patients At Higher Risk Of Life-Threatening Complications

PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 1, 2005--The Medicines Company (NASDAQ: MDCO) today announced that the U.S. Food and Drug Administration (FDA) approved the use of Angiomax(R) (bivalirudin) in patients with or at risk of HIT/HITTS -- heparin-induced thrombocytopenia (HIT) and thrombosis syndrome (HITTS) -- undergoing percutaneous coronary intervention (PCI).